The miR-200a/b precursor could ameliorate renal tubulointerstitial fibrosis through repression of TGF-β2 expression in diabetic nephropathy, suggesting that miR-200 could be a permissible therapeutic target for renal fibrosis [33], [34]. The gene discussed is TGFB2; the disease is diabetic kidney disease.